{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03109873",
      "OrgStudyIdInfo": {
        "OrgStudyId": "16D.639"
      },
      "Organization": {
        "OrgFullName": "Thomas Jefferson University",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer",
      "OfficialTitle": "Pilot Study of Metformin in Head and Neck Cancer and Its Effect on Proinflammatory Cytokines and Exosomes Implicated in Acute and Chronic Toxicity"
    },
    "StatusModule": {
      "StatusVerifiedDate": "December 2020",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "January 5, 2017",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "July 31, 2020",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "July 31, 2020",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "March 6, 2017",
      "StudyFirstSubmitQCDate": "April 5, 2017",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "April 12, 2017",
        "StudyFirstPostDateType": "Actual"
      },
      "ResultsFirstSubmitDate": "October 29, 2019",
      "ResultsFirstSubmitQCDate": "October 29, 2019",
      "ResultsFirstPostDateStruct": {
        "ResultsFirstPostDate": "November 20, 2019",
        "ResultsFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "December 7, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "December 29, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Sidney Kimmel Cancer Center at Thomas Jefferson University",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No",
      "IsUSExport": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "This pilot clinical trial studies how well metformin hydrochloride works in affecting cytokines and exosomes in patients with head and neck cancer. Metformin hydrochloride may reduce the metabolic activity of cancer cells and of surrounding supportive tissues.",
      "DetailedDescription": "PRIMARY OBJECTIVES:\n\nI. To assess the capacity of metformin hydrochloride (metformin) to alter the cytokine and exosome profiles.\n\nII. To assess the capacity of metformin to mitigate known side effects of external beam radiation therapy including inflammation, mucositis, dysphagia, xerostomia, and fatigue.\n\nSECONDARY OBJECTIVES:\n\nI. Assess safety and tolerability of metformin treatment in subjects undergoing external beam radiation treatment for head and neck cancer.\n\nII. To determine the effect of metformin treatment on symptoms of xerostomia as assessed by the Xerostomia Questionnaire (XQ).\n\nIII. To determine the effect of metformin treatment on symptoms of mucositis as assessed by World Health Organization (WHO) classification.\n\nIV. To determine the effect of metformin treatment on symptoms of dysphagia as assessed by the MD Anderson Dysphagia Inventory.\n\nV. To determine the effect of metformin treatment on symptoms of fatigue as assess by the Multidimensional Fatigue Inventory (MFI)."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Larynx",
          "Lip",
          "Oral Cavity",
          "Pharynx"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Early Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Supportive Care",
        "DesignMaskingInfo": {
          "DesignMasking": "Double",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "9",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Arm I (EBRT, metformin hydrochloride)",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Radiation: External Beam Radiation Therapy",
                "Drug: Metformin Hydrochloride"
              ]
            }
          },
          {
            "ArmGroupLabel": "Arm II (EBRT, placebo)",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Radiation: External Beam Radiation Therapy",
                "Other: Placebo"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Radiation",
            "InterventionName": "External Beam Radiation Therapy",
            "InterventionDescription": "Undergo External Beam Radiation Therapy",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Arm I (EBRT, metformin hydrochloride)",
                "Arm II (EBRT, placebo)"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Definitive Radiation Therapy",
                "EBRT",
                "External Beam RT"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Metformin Hydrochloride",
            "InterventionDescription": "Given orally",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Arm I (EBRT, metformin hydrochloride)"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "1,1-Dimethylbiguanide Hydrochloride",
                "1115-70-4",
                "91485",
                "Cidophage",
                "Glucoformin",
                "Glucophage ER",
                "Dimefor"
              ]
            }
          },
          {
            "InterventionType": "Other",
            "InterventionName": "Placebo",
            "InterventionDescription": "Given orally",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Arm II (EBRT, placebo)"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Cytokine/Chemokine Profile",
            "PrimaryOutcomeDescription": "Mixed effects linear regression will be used to model longitudinal measurements of each cytokine.",
            "PrimaryOutcomeTimeFrame": "Up to 1 year"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Mucositis Assessed Using WHO Classification",
            "SecondaryOutcomeDescription": "Analysis will be primarily descriptive. The distribution of swallowing function and mucositis scores will be summarized by arm using means, medians, standard deviations, and ranges.",
            "SecondaryOutcomeTimeFrame": "Up to 1 year"
          },
          {
            "SecondaryOutcomeMeasure": "Objective Response Rate",
            "SecondaryOutcomeDescription": "The objective response rate will be estimated by arm along with an exact 95% binomial confidence interval",
            "SecondaryOutcomeTimeFrame": "Up to 2 years"
          },
          {
            "SecondaryOutcomeMeasure": "Exosome Profile",
            "SecondaryOutcomeDescription": "Longitudinal measurements of exosomes will also be modeled using mixed effects linear regression. This analysis is treated as separate from the cytokine questions and the p-value will not be adjusted.",
            "SecondaryOutcomeTimeFrame": "Up to 1 year"
          },
          {
            "SecondaryOutcomeMeasure": "Incidence of Toxicities",
            "SecondaryOutcomeDescription": "Evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",
            "SecondaryOutcomeTimeFrame": "Up to 2 years"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nSubjects with a diagnosis of head and neck cancer biopsy proven, and who are candidates for radiation therapy\nAll subjects must be able to comprehend and sign a written informed consent document.\n\nExclusion Criteria:\n\nSubjects who are pregnant or may become pregnant during metformin administration; pregnancy testing will be done in conjunction with preradiation protocols\nSubjects on metformin for any reason during the preceding 4 weeks\nDiabetic subjects are eligible if they are not taking metformin or insulin\nSubjects who have received iodinated contrast dye must wait 12 hours prior to starting Metformin. If a CT scan with contrast is scheduled after screening and consent, the metformin cannot be taken until after the CT with contrast has been completed and they have waited 12 hours.\nPatients with plasma creatinine level greater than 1.3 mg/dL\nPatients with plasma bicarbonate less than 22 mEq/L or history of lactic or any other metabolic acidosis\nPatients with history of congestive heart failure\nPatients with myocardial ischemia or peripheral muscle ischemia\nPatients with sepsis or severe infection\nPatients with history of lung disease currently requiring any supplemental oxygen treatment\nPatients scheduled for radiation less than 6 days from enrollment\nPatients with history of hepatic dysfunction or hepatic disease and abnormal liver function tests; patients who have a history of hepatic dysfunction or hepatic disease and normal liver function tests will be eligible to participate\nPatients with a current history (in the past 30 days) of heaving drinking which is defined in accordance with CDC definition as more than 8 drinks per week for women and more than 15 drinks per week for men. A standard drink contains .6 ounces of pure alcohol. Generally, this amount of pure alcohol is found in 12-ounces of beer, 8-ounces of malt liquor, 5-ounces of wine, 1.5-ounces or a \"shot\" of 80-proof distilled spirits or liquor (e.g., gin, rum, vodka, or whiskey). While on study, patients should limit their alcohol consumption to no more than 8 drinks per week for women and no more than 15 drinks per week for men. Patients who feel they cannot comply with this recommendation are not eligible\".\nAll medications are permitted except those that are contraindicated with metformin under current Food and Drug Administration (FDA) recommendations",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "90 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Adam Luginbuhl, MD",
            "OverallOfficialAffiliation": "Sidney Kimmel Cancer Center at Thomas Jefferson University",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Sidney Kimmel Cancer Center at Thomas Jefferson University",
            "LocationCity": "Philadelphia",
            "LocationState": "Pennsylvania",
            "LocationZip": "19107",
            "LocationCountry": "United States"
          }
        ]
      }
    },
    "ReferencesModule": {
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "Sidney Kimmel Cancer Center",
            "SeeAlsoLinkURL": "http://www.kimmelcancercenter.org"
          },
          {
            "SeeAlsoLinkLabel": "Thomas Jefferson University Hospital",
            "SeeAlsoLinkURL": "http://hospitals.jefferson.edu/"
          }
        ]
      }
    }
  },
  "ResultsSection": {
    "ParticipantFlowModule": {
      "FlowGroupList": {
        "FlowGroup": [
          {
            "FlowGroupId": "FG000",
            "FlowGroupTitle": "Arm I (EBRT, Metformin Hydrochloride)",
            "FlowGroupDescription": "Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.\n\nExternal Beam Radiation Therapy: Undergo External Beam Radiation Therapy\n\nMetformin Hydrochloride: Given orally"
          },
          {
            "FlowGroupId": "FG001",
            "FlowGroupTitle": "Arm II (EBRT, Placebo)",
            "FlowGroupDescription": "Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.\n\nExternal Beam Radiation Therapy: Undergo External Beam Radiation Therapy\n\nPlacebo: Given orally"
          }
        ]
      },
      "FlowPeriodList": {
        "FlowPeriod": [
          {
            "FlowPeriodTitle": "Overall Study",
            "FlowMilestoneList": {
              "FlowMilestone": [
                {
                  "FlowMilestoneType": "STARTED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "5"
                      },
                      {
                        "FlowAchievementGroupId": "FG001",
                        "FlowAchievementNumSubjects": "4"
                      }
                    ]
                  }
                },
                {
                  "FlowMilestoneType": "COMPLETED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "5"
                      },
                      {
                        "FlowAchievementGroupId": "FG001",
                        "FlowAchievementNumSubjects": "4"
                      }
                    ]
                  }
                },
                {
                  "FlowMilestoneType": "NOT COMPLETED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "0"
                      },
                      {
                        "FlowAchievementGroupId": "FG001",
                        "FlowAchievementNumSubjects": "0"
                      }
                    ]
                  }
                }
              ]
            }
          }
        ]
      }
    },
    "BaselineCharacteristicsModule": {
      "BaselineGroupList": {
        "BaselineGroup": [
          {
            "BaselineGroupId": "BG000",
            "BaselineGroupTitle": "Arm I (EBRT, Metformin Hydrochloride)",
            "BaselineGroupDescription": "Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.\n\nExternal Beam Radiation Therapy: Undergo External Beam Radiation Therapy\n\nMetformin Hydrochloride: Given orally"
          },
          {
            "BaselineGroupId": "BG001",
            "BaselineGroupTitle": "Arm II (EBRT, Placebo)",
            "BaselineGroupDescription": "Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.\n\nExternal Beam Radiation Therapy: Undergo External Beam Radiation Therapy\n\nPlacebo: Given orally"
          },
          {
            "BaselineGroupId": "BG002",
            "BaselineGroupTitle": "Total",
            "BaselineGroupDescription": "Total of all reporting groups"
          }
        ]
      },
      "BaselineDenomList": {
        "BaselineDenom": [
          {
            "BaselineDenomUnits": "Participants",
            "BaselineDenomCountList": {
              "BaselineDenomCount": [
                {
                  "BaselineDenomCountGroupId": "BG000",
                  "BaselineDenomCountValue": "5"
                },
                {
                  "BaselineDenomCountGroupId": "BG001",
                  "BaselineDenomCountValue": "4"
                },
                {
                  "BaselineDenomCountGroupId": "BG002",
                  "BaselineDenomCountValue": "9"
                }
              ]
            }
          }
        ]
      },
      "BaselineMeasureList": {
        "BaselineMeasure": [
          {
            "BaselineMeasureTitle": "Age, Categorical",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "<=18 years",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Between 18 and 65 years",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "3"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "2"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "5"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": ">=65 years",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "2"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "2"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "4"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Sex: Female, Male",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "Female",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "2"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "1"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "3"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Male",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "3"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "3"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "6"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Ethnicity (NIH/OMB)",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "Hispanic or Latino",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "1"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "1"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Not Hispanic or Latino",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "4"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "4"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "8"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Unknown or Not Reported",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Race (NIH/OMB)",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "American Indian or Alaska Native",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Asian",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Native Hawaiian or Other Pacific Islander",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Black or African American",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "White",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "5"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "4"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "9"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "More than one race",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Unknown or Not Reported",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Region of Enrollment",
            "BaselineMeasureParamType": "Number",
            "BaselineMeasureUnitOfMeasure": "participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineClassTitle": "United States",
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "5"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "4"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "9"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          }
        ]
      }
    },
    "OutcomeMeasuresModule": {
      "OutcomeMeasureList": {
        "OutcomeMeasure": [
          {
            "OutcomeMeasureType": "Primary",
            "OutcomeMeasureTitle": "Cytokine/Chemokine Profile",
            "OutcomeMeasureDescription": "Mixed effects linear regression will be used to model longitudinal measurements of each cytokine.",
            "OutcomeMeasurePopulationDescription": "Due to insufficient accrual, statistical results cannot be reported.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureTimeFrame": "Up to 1 year",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Arm I (EBRT, Metformin Hydrochloride)",
                  "OutcomeGroupDescription": "Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.\n\nExternal Beam Radiation Therapy: Undergo External Beam Radiation Therapy\n\nMetformin Hydrochloride: Given orally"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Arm II (EBRT, Placebo)",
                  "OutcomeGroupDescription": "Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.\n\nExternal Beam Radiation Therapy: Undergo External Beam Radiation Therapy\n\nPlacebo: Given orally"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "0"
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Mucositis Assessed Using WHO Classification",
            "OutcomeMeasureDescription": "Analysis will be primarily descriptive. The distribution of swallowing function and mucositis scores will be summarized by arm using means, medians, standard deviations, and ranges.",
            "OutcomeMeasurePopulationDescription": "Due to insufficient accrual, statistical results cannot be reported.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureTimeFrame": "Up to 1 year",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Arm I (EBRT, Metformin Hydrochloride)",
                  "OutcomeGroupDescription": "Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.\n\nExternal Beam Radiation Therapy: Undergo External Beam Radiation Therapy\n\nMetformin Hydrochloride: Given orally"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Arm II (EBRT, Placebo)",
                  "OutcomeGroupDescription": "Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.\n\nExternal Beam Radiation Therapy: Undergo External Beam Radiation Therapy\n\nPlacebo: Given orally"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "0"
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Objective Response Rate",
            "OutcomeMeasureDescription": "The objective response rate will be estimated by arm along with an exact 95% binomial confidence interval",
            "OutcomeMeasurePopulationDescription": "Due to insufficient accrual, statistical results cannot be reported.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureTimeFrame": "Up to 2 years",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Arm I (EBRT, Metformin Hydrochloride)",
                  "OutcomeGroupDescription": "Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.\n\nExternal Beam Radiation Therapy: Undergo External Beam Radiation Therapy\n\nMetformin Hydrochloride: Given orally"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Arm II (EBRT, Placebo)",
                  "OutcomeGroupDescription": "Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.\n\nExternal Beam Radiation Therapy: Undergo External Beam Radiation Therapy\n\nPlacebo: Given orally"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "0"
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Exosome Profile",
            "OutcomeMeasureDescription": "Longitudinal measurements of exosomes will also be modeled using mixed effects linear regression. This analysis is treated as separate from the cytokine questions and the p-value will not be adjusted.",
            "OutcomeMeasurePopulationDescription": "Due to insufficient accrual, statistical results cannot be reported.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureTimeFrame": "Up to 1 year",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Arm I (EBRT, Metformin Hydrochloride)",
                  "OutcomeGroupDescription": "Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.\n\nExternal Beam Radiation Therapy: Undergo External Beam Radiation Therapy\n\nMetformin Hydrochloride: Given orally"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Arm II (EBRT, Placebo)",
                  "OutcomeGroupDescription": "Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.\n\nExternal Beam Radiation Therapy: Undergo External Beam Radiation Therapy\n\nPlacebo: Given orally"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "0"
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Incidence of Toxicities",
            "OutcomeMeasureDescription": "Evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",
            "OutcomeMeasurePopulationDescription": "Due to insufficient accrual, statistical results cannot be reported.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureTimeFrame": "Up to 2 years",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Arm I (EBRT, Metformin Hydrochloride)",
                  "OutcomeGroupDescription": "Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.\n\nExternal Beam Radiation Therapy: Undergo External Beam Radiation Therapy\n\nMetformin Hydrochloride: Given orally"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Arm II (EBRT, Placebo)",
                  "OutcomeGroupDescription": "Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.\n\nExternal Beam Radiation Therapy: Undergo External Beam Radiation Therapy\n\nPlacebo: Given orally"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "0"
                      }
                    ]
                  }
                }
              ]
            }
          }
        ]
      }
    },
    "AdverseEventsModule": {
      "EventsFrequencyThreshold": "5",
      "EventsTimeFrame": "baseline through one year after completion of treatment",
      "EventGroupList": {
        "EventGroup": [
          {
            "EventGroupId": "EG000",
            "EventGroupTitle": "Arm I (EBRT, Metformin Hydrochloride)",
            "EventGroupDescription": "Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.\n\nExternal Beam Radiation Therapy: Undergo External Beam Radiation Therapy\n\nMetformin Hydrochloride: Given orally",
            "EventGroupDeathsNumAffected": "0",
            "EventGroupDeathsNumAtRisk": "5",
            "EventGroupSeriousNumAffected": "0",
            "EventGroupSeriousNumAtRisk": "5",
            "EventGroupOtherNumAffected": "4",
            "EventGroupOtherNumAtRisk": "5"
          },
          {
            "EventGroupId": "EG001",
            "EventGroupTitle": "Arm II (EBRT, Placebo)",
            "EventGroupDescription": "Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.\n\nExternal Beam Radiation Therapy: Undergo External Beam Radiation Therapy\n\nPlacebo: Given orally",
            "EventGroupDeathsNumAffected": "0",
            "EventGroupDeathsNumAtRisk": "4",
            "EventGroupSeriousNumAffected": "0",
            "EventGroupSeriousNumAtRisk": "4",
            "EventGroupOtherNumAffected": "3",
            "EventGroupOtherNumAtRisk": "4"
          }
        ]
      },
      "OtherEventList": {
        "OtherEvent": [
          {
            "OtherEventTerm": "Xerostomia",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventAssessmentType": "Non-systematic Assessment",
            "OtherEventNotes": "Dry mouth",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "5"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "4"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dysphagia",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventAssessmentType": "Non-systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "5"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "4"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Fatigue",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventAssessmentType": "Non-systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "5"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "4"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dysgeusia",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventAssessmentType": "Non-systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "5"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "4"
                }
              ]
            }
          }
        ]
      }
    },
    "MoreInfoModule": {
      "CertainAgreement": {
        "AgreementPISponsorEmployee": "Yes"
      },
      "PointOfContact": {
        "PointOfContactTitle": "Dr. Adam Luginbuhl",
        "PointOfContactOrganization": "Sidney Kimmel Cancer Center at Thomas Jefferson University",
        "PointOfContactEMail": "adam.luginbuhl@jefferson.ed",
        "PointOfContactPhone": "215-240-0748"
      }
    }
  },
  "DocumentSection": {
    "LargeDocumentModule": {
      "LargeDocList": {
        "LargeDoc": [
          {
            "LargeDocTypeAbbrev": "Prot_SAP",
            "LargeDocHasProtocol": "Yes",
            "LargeDocHasSAP": "Yes",
            "LargeDocHasICF": "No",
            "LargeDocLabel": "Study Protocol and Statistical Analysis Plan",
            "LargeDocDate": "June 20, 2019",
            "LargeDocUploadDate": "10/08/2019 14:55",
            "LargeDocFilename": "Prot_SAP_000.pdf"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000006258",
            "ConditionMeshTerm": "Head and Neck Neoplasms"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000009371",
            "ConditionAncestorTerm": "Neoplasms by Site"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M9987",
            "ConditionBrowseLeafName": "Laryngeal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8500",
            "ConditionBrowseLeafName": "Head and Neck Neoplasms",
            "ConditionBrowseLeafAsFound": "Head and Neck Cancer",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC08",
            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC09",
            "ConditionBrowseBranchName": "Ear, Nose, and Throat Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "D000008687",
            "InterventionMeshTerm": "Metformin"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000007004",
            "InterventionAncestorTerm": "Hypoglycemic Agents"
          },
          {
            "InterventionAncestorId": "D000045505",
            "InterventionAncestorTerm": "Physiological Effects of Drugs"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M10819",
            "InterventionBrowseLeafName": "Metformin",
            "InterventionBrowseLeafAsFound": "Centered",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M9206",
            "InterventionBrowseLeafName": "Hypoglycemic Agents",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Hypo",
            "InterventionBrowseBranchName": "Hypoglycemic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}